MedTrace Logo

Glioblastoma and Individualized Therapies

NCT05356312 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-03-01

No results posted yet for this study

Summary

The treatment of patients with World Health Organization (WHO) grade 4 malignant glioma has not seen any significant breakthrough the past years. Following surgery and radio / chemotherapy patients still experience a very high recurrence risk and the prognosis is dismal. The investigators observed patients with grade IV malignant glioma receiving individualized treatment based on their molecular profile including fully personalized vaccines.

Conditions

  • Glioma, Malignant

Interventions

BIOLOGICAL

Vaccination

Personalized neoantigen vaccination

Sponsors & Collaborators

  • Zentrum fur Humangenetik Tuebingen

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05356312 on ClinicalTrials.gov